Literature DB >> 8611715

Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10.

C Sgadari1, A L Angiolillo, G Tosato.   

Abstract

Interleukin 12 (IL-12), a multifunctional cytokine produced by macrophages and B-cell lines, induces interferon-gamma (IFN-gamma) production, stimulates growth of both T and natural killer cells, promotes Th1-type helper T-cell responses, and inhibits neovascularization. Because the human interferon-inducible protein 10 (IP-10) can also inhibit neovascularization, we tested whether IP-10, induced by IL-12 through the intermediate IFN-gamma, might be a mediator of IL-12 angiogenesis inhibition. We report here that murine IL-12 profoundly inhibited basic fibroblast growth factor (bFGF)-induced Matrigel neovascularization in vivo, and that this effect of IL-12 was neutralized by systemic administration of antibodies to either murine IFN-gamma or IP-10. Murine IL-12 induced murine IP-10 expression in mouse splenocytes, and human IFN-gamma induced human IP-10 expression in purified human endothelial cells, suggesting that IL-12 can induce IP-10 expression in certain cells. These results document the important role of IP-10 as a mediator of angiogenesis inhibition by IL-12, and raise the possibility that IP-10 may also contribute to the antitumor effect of IL-12.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611715

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  106 in total

Review 1.  Angiogenesis inhibitors.

Authors:  T R Tennant; C W Rinker-Schaeffer; W M Stadler
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

2.  Interleukin-12 regulates chemokine gene expression during the early immune response to Leishmania major.

Authors:  Colby Zaph; Phillip Scott
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

3.  Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis.

Authors:  M Watanabe; K L McCormick; K Volker; J R Ortaldo; J M Wigginton; M J Brunda; R H Wiltrout; W E Fogler
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

4.  Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.

Authors:  Justin Kline; Long Zhang; Lauren Battaglia; Kenneth S Cohen; Thomas F Gajewski
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

5.  IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

Authors:  J M Wigginton; E Gruys; L Geiselhart; J Subleski; K L Komschlies; J W Park; T A Wiltrout; K Nagashima; T C Back; R H Wiltrout
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 6.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

7.  Cloning and identification of an angiostatic molecule IP10/crg -2.

Authors:  Zhi-Guo Liu; Jing-Hua Yang; Hua-Zhang An; Hai-Yan Wang; Feng-Tian He; Zhe-Yi Han; Ying Han; Han-Ping Wu; Bing Xiao; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

Review 8.  Angiogenesis: possibilities for therapeutic interventions.

Authors:  W Wynendaele; A T van Oosterom; A Pawinski; E A de Bruijn; R A Maes
Journal:  Pharm World Sci       Date:  1998-12

Review 9.  Immunobiology of interleukin-12.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

10.  Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.

Authors:  Caroline Aspord; Laetitia Tramcourt; Claire Leloup; Jean-Paul Molens; Marie-Therese Leccia; Julie Charles; Joel Plumas
Journal:  J Invest Dermatol       Date:  2014-04-21       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.